PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary…

Continue ReadingPhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry